STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [Form 4] HAEMONETICS CORP Insider Trading Activity

Haemonetics (HAE) EVP and General Counsel receives 28,424 RSUs, 2,913 shares withheld for taxes

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Haemonetics Corporation EVP and General Counsel Michelle L. Basil reported routine equity compensation activity. She received a grant of 28,424 restricted stock units, each convertible into one share of common stock, under the company’s 2019 long-term incentive plan. The RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third.

The filing also shows 2,913 shares of common stock withheld at $56.29 per share to satisfy tax obligations tied to previously granted RSUs, which is not an open-market sale. After these transactions, she directly holds 40,405 shares of common stock, including unvested RSUs.

Positive

  • None.

Negative

  • None.
Insider Basil Michelle L
Role EVP and General Counsel
Type Security Shares Price Value
Tax Withholding Common Stock 2,913 $56.29 $164K
Grant/Award Common Stock 28,424 $0.00 --
Holdings After Transaction: Common Stock — 40,405 shares (Direct, null)
Footnotes (1)
  1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. This number includes unvested RSUs previously reported. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
RSUs granted 28,424 units Equity award to EVP and General Counsel
Shares withheld for taxes 2,913 shares Withholding on RSU vesting
Withholding price $56.29 per share Value used for tax-withholding shares
Shares after award entry 68,829 shares Total following RSU-related acquisition entry
Shares held after withholding 40,405 shares Direct holdings including unvested RSUs
Vesting year 1 40% of award First anniversary of grant
Vesting year 2 40% of award Second anniversary of grant
Vesting year 3 20% of award Third anniversary of grant
restricted stock units ("RSUs") financial
"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
tax obligations financial
"Represents shares withheld for tax obligations in connection with the vesting of certain RSUs"
Long-Term Incentive Compensation Plan financial
"RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"
vest financial
"The RSUs vest in three annual installments with forty percent vesting on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
contingent right financial
"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Basil Michelle L
(Last)(First)(Middle)
125 SUMMER STREET
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP and General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026F2,913(1)D$56.2940,405(2)D
Common Stock05/15/2026A28,424(3)A(4)68,829(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. This number includes unvested RSUs previously reported.
3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
/s/ Thomas V. Powers, attorney-in-fact for Ms. Basil05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Haemonetics (HAE) report for Michelle L. Basil?

Haemonetics reported that EVP and General Counsel Michelle L. Basil received a grant of 28,424 restricted stock units. These RSUs represent potential future shares of common stock as part of her long-term incentive compensation.

How many Haemonetics (HAE) shares were withheld for taxes in this Form 4?

The Form 4 shows 2,913 shares of Haemonetics common stock were withheld at $56.29 per share to cover tax obligations related to the vesting of previously granted RSUs, rather than sold in the open market.

What is the vesting schedule of Michelle L. Basil’s new RSU award at Haemonetics (HAE)?

The new RSU award vests over three years: 40% of the total award vests on the first anniversary, another 40% on the second anniversary, and the remaining 20% on the third anniversary of the grant date.

How many Haemonetics (HAE) shares does Michelle L. Basil hold after these transactions?

After the reported transactions, Michelle L. Basil directly holds 40,405 shares of Haemonetics common stock. This figure includes unvested restricted stock units previously reported as part of her equity compensation.

Are the securities granted to Michelle L. Basil at Haemonetics (HAE) in the form of RSUs?

Yes. The award is in the form of restricted stock units (RSUs) issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan, with each RSU representing a contingent right to receive one share of common stock when vested.

Does the Haemonetics (HAE) Form 4 show an open-market sale by Michelle L. Basil?

No. The disposition reported involves 2,913 shares withheld to pay tax obligations on RSU vesting. This is a tax-withholding transaction, not an open-market sale, and is common in equity compensation arrangements.